Histoplasmosis-associated hospitalizations in the United States, 2001-2012

Open Forum Infectious Diseases

Volumn 3, Issue 1, 2016, Pages

  Benedict, Kaitlin ^a   Derado, Gordana ^a   Mody, Rajal K ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Histoplasma; Histoplasmosis; Hospitalization; United States

Indexed keywords

AGE; ARTICLE; COMORBIDITY; DEATH; FEMALE; GENDER; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HISTOPLASMA; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; UNITED STATES;

EID: 85000751833     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv219     Document Type: Article

References (13)

1. HCUP National Inpatient Sample 2012 and Nationwide Inpatient Sample 2001-2011. Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality, Rockville, MD. Available at: www.hcup-us.ahrq.gov/ nisoverview.jsp.
2. Trend Weights for 1993-2011 HCUP NIS Data. Healthcare Cost and Utilization Project (HCUP). 2015. Agency for Healthcare Research and Quality, Rockville, MD. Available at: www.hcup-us.ahrq.gov/db/nation/nis/trendwghts.jsp. Accessed 14 September 2015.
3. Gillum B, Graves E, Kozak LJ. Trends in hospital utilization: United States, 1988-92. Vital Health Stat 13 1996; 1-71.
4. Chu JH, Feudtner C, Heydon K, et al. Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis 2006; 42:822-5.
5. Baddley JW, Winthrop KL, Patkar NM, et al. Geographic distribution of endemic fungal infections among older persons, United States. Emerg Infect Dis 2011; 17:1664-9.
6. Novosad SA, Winthrop KL. Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis 2014; 58:1587-98.
7. Vergidis P, Avery RK, Wheat LJ, et al. Histoplasmosis complicating tumor necrosis factor-alpha blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis 2015; 61:409-17.
8. Kauffman CA, Freifeld AG, Andes DR, et al. Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis 2014; 16:213-24.
9. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990; 69:361-74.
10. Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30:S5-14.
11. Myint T, Al-Hasan MN, Ribes JA, et al. Temporal trends, clinical characteristics, and outcomes of histoplasmosis in a tertiary care center in Kentucky, 2000 to 2009. J Int Assoc Provid AIDS Care 2014; 13:100-5.
12. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807-25.
13. Benedict K, Mody R. Epidemiology of histoplasmosis outbreaks in the United States, 1938-2013. Emerg Infect Dis 2016; 22:387-95.